NASDAQ:RPRX
Royalty Pharma plc Stock News
$27.41
+1.02 (+3.87%)
At Close: May 31, 2024
Royalty Pharma Acquires Royalty Interest in Seltorexant From Minerva Neurosciences
08:30am, Tuesday, 19'th Jan 2021
NEW YORK and WALTHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty Pharma will acquire Minerva
Royalty Pharma increases quarterly dividend by 13% to 17 cents a share
08:05am, Friday, 08'th Jan 2021
Royalty Pharma plc said Friday its board has approved a 13% increase in its quarterly dividend to 17 cents a share. The dividend will be paid March 15 to shareholders of record as of Feb. 19.
Royalty Pharma Announces 13% Dividend Increase
08:00am, Friday, 08'th Jan 2021
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2021 of $0.17 per class A sha
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 12
04:15pm, Thursday, 07'th Jan 2021
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that management will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12,
Royalty Pharma Announces Charitable Gifts to Support COVID-19 Research at Leading Hospitals and Universities
08:30am, Tuesday, 22'nd Dec 2020
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced charitable contributions totaling $7,660,000 to support important COVID-19 research at The Rockefeller Uni
Royalty Pharma Announces Expansion of Leadership Team
08:12am, Monday, 21'st Dec 2020
NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team:
Royalty Pharma Acquires Royalty Interest in ORLADEYO and BCX9930 From BioCryst Pharmaceuticals
08:45am, Monday, 07'th Dec 2020
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Athyrium Capital Management, LP today ann
Royalty Pharma: Business Model May Be Over-Sold, But Shares Are Undervalued & Could Trade >$80
05:34pm, Friday, 27'th Nov 2020
Royalty Pharma invests in biopharmaceutical royalty streams and has deployed $18bn of capital into the space since 1996 - ~50% of all deployed capital. Its portfolio of assets includes royalties from
Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q3 2020 Results - Earnings Call Transcript
12:09pm, Wednesday, 11'th Nov 2020
Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q3 2020 Results - Earnings Call Transcript
Royalty Pharma Reports Third Quarter 2020 Results
05:40pm, Tuesday, 10'th Nov 2020
NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2020 and updated full-year 2020 guidance for Adjusted Cash Recei
Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation
07:30am, Monday, 02'nd Nov 2020
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.'s cystic fibrosis (C
